Jaydess

Levonorgestrel, the active ingredient in Jaydess, is a progestin presented as a 13.5 mg intrauterine system for intrauterine use. It prevents pregnancy by providing hormonal contraception for women of reproductive age.

GNH USA supplies Jaydess as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Levonorgestrel delivered via the Jaydess intrauterine system is used within the hormonal contraceptive pathway to prevent unintended pregnancy.

- Contraception: provides highly effective reversible birth control for women of child‑bearing age. - Extended‑duration contraception (up to 3 years): reduces the need for frequent device replacement. - Fertility planning: allows rapid return to fertility after device removal.

Common side effects are generally mild and related to the local hormonal release.

Common Side Effects: - Irregular bleeding or spotting. - Amenorrhea (absence of periods). - Cramping or pelvic discomfort during or after insertion. - Breast tenderness. - Mood changes.

Serious or Rare Side Effects: - Uterine perforation during insertion. - Device expulsion. - Pelvic inflammatory disease or infection. - Ectopic pregnancy if contraception fails. - Severe allergic reaction to device components.

Before insertion, clinicians should assess patient suitability and counsel on risks.

- Contraindications: avoid in women with active pelvic infection, unexplained vaginal bleeding, or known hypersensitivity to levonorgestrel. - Screening: confirm non‑pregnant status and evaluate uterine anatomy. - Follow‑up: schedule post‑insertion check to verify placement. - Pregnancy monitoring: advise immediate medical review if pregnancy is suspected. - Medication review: consider interactions with enzyme‑inducing drugs. - Store at ambient temperature: keep in original packaging, protect from moisture and direct sunlight.

Levonorgestrel IUS may have pharmacokinetic interactions with drugs that affect steroid metabolism.

Major Interactions (Avoid): - Rifampin and other strong enzyme inducers. - Anticonvulsants such as phenytoin, carbamazepine, or phenobarbital. - Antiretroviral efavirenz. - St. John’s wort (hypericum perforatum).

Moderate Interactions (Monitor Closely): - Combined hormonal contraceptives used concurrently. - Hormone replacement therapy. - Certain antibiotics that may reduce contraceptive efficacy (e.g., griseofulvin).